Patents by Inventor Anjana Rao

Anjana Rao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160052981
    Abstract: Disclosed are methods of identifying an agent that modulates an NFAT regulator protein. One such method comprises contacting at least one test agent with recombinant cell comprising at least one NFAT regulator protein or fragment or derivative thereof, assessing the effect of the test agent on an activity, interaction, expression, or binding to the NFAT regulator protein or fragment or derivative thereof, and identifying the test agent that has an effect on an activity, interaction, expression, or binding to the NFAT regulator protein or fragment or derivative thereof, whereby the identified test agent is characterized as an agent that modulates an NFAT regulator protein.
    Type: Application
    Filed: August 21, 2015
    Publication date: February 25, 2016
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Anjana Rao, Stefan Feske, Patrick Hogan, Yousang Gwack
  • Patent number: 9163078
    Abstract: Disclosed are methods of identifying an agent that modulates an NFAT regulator protein. One such method comprises contacting at least one test agent with a recombinant cell comprising at least one NFAT regulator protein or fragment or derivative thereof, assessing the effect of the test agent on an activity, interaction, expression, or binding to the NFAT regulator protein or fragment or derivative thereof, and identifying the test agent that has an effect on an activity, interaction, expression, or binding to the NFAT regulator protein or fragment or derivative thereof, whereby the identified test agent is characterized as an agent that modulates an NFAT regulator protein.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: October 20, 2015
    Assignee: Children's Medical Center Corporation
    Inventors: Anjana Rao, Stefan Feske, Patrick Hogan, Yousang Gwack
  • Patent number: 9115386
    Abstract: The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.
    Type: Grant
    Filed: September 28, 2009
    Date of Patent: August 25, 2015
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Anjana Rao, Mamta Tahiliani, Kian Peng Koh, Suneet Agarwal, Aravind Iyer
  • Publication number: 20140294873
    Abstract: The invention provides a screening assay for selecting inhibitors of NFAT:Transcription factor interactions. The invention also provides compositions and methods for inhibiting immune response in a subject.
    Type: Application
    Filed: November 8, 2012
    Publication date: October 2, 2014
    Applicant: Children Medical Center Corporation
    Inventors: Srimoyee Ghosh, Anjana Rao, Patrick G. Hogan
  • Publication number: 20140093542
    Abstract: Embodiments of the inventions relate to modulating NFAT activity, modulating store-operated Ca2+ entry into a cell and treating and/or preventing hyperactivity or inappropriate immune response by inhibiting the expression or activities of septin 4 (SEPT 4) and septin 5 (SEPT 5) proteins involved in the calcineurin/NFAT axis and T-cell activation.
    Type: Application
    Filed: October 10, 2011
    Publication date: April 3, 2014
    Applicant: IMMUNE DISEASE INSTITUTE, INC.
    Inventors: Anjana Rao, Patrick Hogan, Sonia Sharma
  • Patent number: 8399185
    Abstract: Disclosed are methods of identifying an agent that modulates an NFAT regulator protein. One such method comprises contacting at least one test agent with a recombinant cell comprising at least one NFAT regulator protein or fragment or derivative thereof, assessing the effect of the test agent on an activity, interaction, expression, or binding to the NFAT regulator protein or fragment or derivative thereof, and identifying the test agent that has an effect on an activity, interaction, expression, or binding to the NFAT regulator protein or fragment or derivative thereof, whereby the identified test agent is characterized as an agent that modulates an NFAT regulator protein.
    Type: Grant
    Filed: January 5, 2007
    Date of Patent: March 19, 2013
    Assignee: Immune Disease Institute, Inc.
    Inventors: Anjana Rao, Stefan Feske, Patrick Hogan, Yousang Gwack
  • Patent number: 8394778
    Abstract: Embodiments of the inventions relate to modulating NFAT activity, modulating store-operated Ca2+ entry into a cell and treating and/or preventing hyperactivity or inappropriate immune response by inhibiting the expression or activities of proteins involved in the calcineurin/NFAT axis.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: March 12, 2013
    Assignee: Immune Disease Institute, Inc.
    Inventors: Anjana Rao, Patrick Hogan, Sonia Sharma
  • Publication number: 20120272343
    Abstract: This invention relates to knockout mice for the Ca2+ sensor membrane protein STIM-1, STIM-2, or both, as well as cell lines from these knockout mice. Provided herein are various methods of use of isolated with knockout STIM-1 and/or STIM-2.
    Type: Application
    Filed: June 29, 2012
    Publication date: October 25, 2012
    Applicant: IMMUNE DISEASE INSTITUTE, INC.
    Inventors: Masatsugu Oh-Hora, Patrick Hogan, Stefan Feske, Anjana Rao
  • Publication number: 20120264231
    Abstract: The methods and systems described herein are based, in part, on the discovery that STIM modulates calcium release from store-operated channels through a direct interaction with the ORAI channel. Based on this discovery, methods and systems are described herein for identifying an agent that modulates calcium flux through the ORAI channel and/or regulates intracellular calcium via the ORAI channel. The methods and systems can also be used to detect an interaction between STIM and a functional ORAI channel.
    Type: Application
    Filed: June 21, 2010
    Publication date: October 18, 2012
    Applicant: IMMUNE DISEASE INSTITUTE, INC.
    Inventors: Patrick Hogan, Yubin Zhou, Anjana Rao, Paul Meraner, Danya Bess Machnes
  • Publication number: 20110269174
    Abstract: Disclosed are methods of identifying an agent that modulates an NFAT regulator protein. One such method comprises contacting at least one test agent with a recombinant cell comprising at least one NFAT regulator protein or fragment or derivative thereof, assessing the effect of the test agent on an activity, interaction, expression, or binding to the NFAT regulator protein or fragment or derivative thereof, and identifying the test agent that has an effect on an activity, interaction, expression, or binding to the NFAT regulator protein or fragment or derivative thereof, whereby the identified test agent is characterized as an agent that modulates an NFAT regulator protein.
    Type: Application
    Filed: June 15, 2011
    Publication date: November 3, 2011
    Applicant: Immune Disease Institute, Inc.
    Inventors: Anjana RAO, Stefan Feske, Patrick Hogan, Yousang Gwack
  • Patent number: 8048864
    Abstract: Embodiments of the inventions relates to modulating NFAT activity, modulating store-operated Ca2+ entry into a cell and treating and/or preventing hyperactivity or inappropriate immune response by inhibiting the expression or activities of proteins involved in the calcineurin/NFAT axis.
    Type: Grant
    Filed: October 8, 2009
    Date of Patent: November 1, 2011
    Assignee: Immune Disease Institute, Inc.
    Inventors: Anjana Rao, Patrick Hogan, Sonia Sharma
  • Publication number: 20110236894
    Abstract: The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.
    Type: Application
    Filed: September 28, 2009
    Publication date: September 29, 2011
    Applicant: IMMUNE DISEASE INSTITUTE, INC.
    Inventors: Anjana Rao, Mamta Tahiliani, Kian Peng Koh, Suneet Agarwal, Aravind Iyer
  • Publication number: 20110212100
    Abstract: This invention provides methods and compositions for modulating the development and/or expansion of Th17 cells for use, for example, in the treatment of autoimmune diseases, persistent inflammatory diseases, infectious diseases and other Th17 related and/or IL-17 related diseases.
    Type: Application
    Filed: August 15, 2008
    Publication date: September 1, 2011
    Inventors: Tracy Keller, Malcolm Whitman, Mark S. Sundrud, Anjana Rao
  • Publication number: 20100323371
    Abstract: This invention relates to knockout mice for the Ca2+ sensor membrane protein STIM-1, STIM-2, or both, as well as cell lines from these knockout mice. Provided herein are various methods of use of isolated with knockout STIM-1 and/or STIM-2.
    Type: Application
    Filed: July 10, 2008
    Publication date: December 23, 2010
    Applicant: IMMUNE DISEASE INSTITUTE, INC.
    Inventors: Masatsugu Oh-Hora, Patrick Hogan, Stefan Feske, Anjana Rao
  • Patent number: 7816490
    Abstract: Isolated peptide fragments of the conserved regulatory domain of NFAT protein capable of inhibiting protein-protein interaction between calcineurin and NFAT, or a biologically active analog thereof are described. Isolated polynucleotides and gene therapy vectors encoding such peptide fragments are also described. In addition, methods for treating immune-related diseases or conditions and methods for high throughput screening of candidate agents are described. Pharmaceutical compositions are also provided.
    Type: Grant
    Filed: October 28, 2008
    Date of Patent: October 19, 2010
    Assignee: Immune Disease Institute, Inc.
    Inventors: Patrick G. Hogan, Anjana Rao, Jose Aramburu
  • Publication number: 20100135910
    Abstract: The present invention provides methods for identifying compounds capable of modulating anergy by inhibiting the production or activity of anergy associated E3 ubiquitin ligases or by altering the interaction between a ligase and its substrate.
    Type: Application
    Filed: June 3, 2009
    Publication date: June 3, 2010
    Inventors: Anjana Rao, Patrick G. Hogan, Vigo Heissmeyer
  • Publication number: 20090186422
    Abstract: Isolated peptide fragments of the conserved regulatory domain of NFAT protein capable of inhibiting protein-protein interaction between calcineurin and NFAT, or a biologically active analog thereof are described. Isolated polynucleotides and gene therapy vectors encoding such peptide fragments are also described. In addition, methods for treating immune-related diseases or conditions and methods for high throughput screening of candidate agents are described. Pharmaceutical compositions are also provided.
    Type: Application
    Filed: October 28, 2008
    Publication date: July 23, 2009
    Inventors: Patrick G. Hogan, Anjana Rao, Jose Aramburu
  • Publication number: 20090178146
    Abstract: Disclosed are methods of identifying an agent that modulates an NFAT regulator protein. One such method comprises contacting at least one test agent with a recombinant cell comprising at least one NFAT regulator protein or fragment or derivative thereof, assessing the effect of the test agent on an activity, interaction, expression, or binding to the NFAT regulator protein or fragment or derivative thereof, and identifying the test agent that has an effect on an activity, interaction, expression, or binding to the NFAT regulator protein or fragment or derivative thereof, whereby the identified test agent is characterized as an agent that modulates an NFAT regulator protein.
    Type: Application
    Filed: January 5, 2007
    Publication date: July 9, 2009
    Applicant: IMMUNE DISEASE INSTITUTE, INC.
    Inventors: Anjana Rao, Stefan Feske, Patrick Hogan, Yousang Gwack
  • Publication number: 20070274915
    Abstract: The present invention provides methods for identifying compounds capable of modulating anergy by inhibiting the production or activity of anergy associated E3 ubiquitin ligases or by altering the interaction between a ligase and its substrate.
    Type: Application
    Filed: March 29, 2004
    Publication date: November 29, 2007
    Inventors: Anjana Rao, Patrick Hogan, Vigo Heissmeyer
  • Publication number: 20070042403
    Abstract: Isolated peptide fragments of the conserved regulatory domain of NFAT protein capable of inhibiting protein-protein interaction between calcineurin and NFAT, or a biologically active analog thereof are described. Isolated polynucleotides and gene therapy vectors encoding such peptide fragments are also described. In addition, methods for treating immune-related diseases or conditions and methods for high throughput screening of candidate agents are described. Pharmaceutical compositions are also provided.
    Type: Application
    Filed: June 23, 2006
    Publication date: February 22, 2007
    Inventors: Patrick Hogan, Anjana Rao, Jose Aramburu